Precipio Business Summary

Precipio, Inc. (PRPO) is a specialty cancer diagnostics company that generates revenue through a dual-model approach consisting of high-complexity diagnostic services and the sale of proprietary laboratory products. The company operates two primary segments: Pathology Services, which provides specialized blood cancer testing to physician practices and hospitals, and the Products Division, which commercializes patented technologies such as HemeScreen (a rapid genetic mutation screening panel) and IV-Cell (a universal cell culture medium). In fiscal year 2025, Precipio achieved a significant operational pivot, reporting $24.0 million in revenue—a 30% year-over-year increase—and reaching positive Adjusted EBITDA and operating cash flow. Within the competitive landscape, Precipio competes against industry giants like NeoGenomics, Guardant Health, and Labcorp; however, it distinguishes itself as a high-accuracy niche provider that utilizes proprietary technology to reduce misdiagnosis rates and laboratory turnaround times compared to traditional high-volume "mega-labs." The company was co-founded by its current Chief Executive Officer, Ilan Danieli, alongside Chief Operating Officer Ahmed Zaki Sabet and Chief Technology Officer Dr. Ayman Mohamed. Danieli brings a strong pedigree in operational management from Osiris and Laurus Capital Management, while Dr. Mohamed leads the technical development of the firm's core IP, including the BloodHound and HemeScreen platforms. The executive team is rounded out by CFO Matthew Gage, who possesses over 30 years of corporate finance experience. Precipio’s governance is anchored by a board of industry veterans, including Chairman Richard Sandberg—the founder of Dianon Systems (acquired by Labcorp for $650M)—and Director Ron Andrews, formerly the President of the Genetic Science Division at Thermo Fisher Scientific. Notable institutional interest is highlighted by the significant ownership stake held by billionaire biotech investor Randal J. Kirk.